Drug firm Wockhardt today said that the UK health regulator had completed inspection of its Chikalthana plant in Aurangabad, Maharashtra without making any critical observations.
Wockhardt explained in a filing to BSE that the inspection of their manufacturing unit at L-1, Chikalthana, Aurangabad, Maharashtra by UK MHRA had been completed without any critical observations and the functioning of the unit had been approved. It further said that the said audit was according to schedule. In October 2013, the UK regulator had withdrew the GMP certificate to the plant in Chikalthana and had also initiated recall of 5 prescription medicines from there.
In December 2015, Wockhardt had received a GMP - good manufacturing practice certificate from the United Kingdom health regulator for its plant in Chikalthana after an inspection.
In December 2015, Wockhardt had received a GMP - good manufacturing practice certificate from the United Kingdom health regulator for its plant in Chikalthana after an inspection.
Wockhardt share price was trading at Rs.926.50 per scrip on the BSE, up 2.28 per cent, from its previous close. Wockhardt share price opened at Rs. 912.80 and was last traded at Rs. 867 with the drop of over 4%. The stock traded at the intraday high of Rs. 945 and the intraday low of Rs. 855. Wockhardt share price today closed at Rs. 863, lower than its previous close of Rs. 904.60. A total of 48.81 lakhs were traded at the NSE counter today against its average traded volume of 1954477 for twenty days. Wockhardt is among the top 500 shares identified by Dynamic Levels for the quarter. Wockhardt has the PE of 30.71and the monthly return of 10.52%.
Potential investors are all the time on the lookout for stocks that can rake in good profits. Wockhardt share price has posted good performance recently. Dynamic Levels share market researchers have come up with some great stocks which are either proven multibaggers or are on their ways to becoming the same. Wockhardt is one such stock which can be a great investment.
Wockhardt is a pharmaceutical and biotechnology company. It has a strong presence all across the globe. It is a global company with manufacturing plants in India, Ireland, UK, France and US, and subsidiaries in US, Ireland, UK and France. The core competence of Wockhardt lies in producing formulations, biopharmaceuticals, nutrition products, vaccines and APIs - active pharmaceutical ingredients.
It offers good quality and medicines which are affordable to the local people. The workforce of Wockhardt comprises 86,000 employees from 21 different countries all over the world. It has twelve manufacturing units and three research centres. The business of this company ranges from marketing of pharmaceutical and bio-pharmaceutical formulations, Vaccines and Active Pharmaceutical Ingredients.
The company has created technology which successfully manufactures all types of dosage. It has highly skilled technicians operating in 12 manufacturing units which are US FDA, EMEA, USA and Europe. The manufacturing plant in Aurangabad has six manufacturing facilities as well as different types of formulation. The Wockhardt Biotech Park has world class technology and has created its own benchmark in it.
Wockhardt has a multi-disciplinary research and development (R&D) programme with over 607 scientists, including more than 80 doctorates, in the areas of pharmaceutical research, Biotechnology and Genomics research, Novel Drug Delivery Systems and Novel Drug Programme.
No comments:
Post a Comment